Gelonghui May 26 丨 Hengrui Pharmaceutical (600276)(600276superslotsnodepositbonus.SH) Announcementsuperslotsnodepositbonus, SHR-A1921 for injection from the company's subsidiary Suzhou Shengdiya Biomedical Co., Ltd. is planned to be included in the publicity list of breakthrough treatment varieties by the Center for Drug Evaluation of the State Food and Drug Administration (known as the "Center for Drug Evaluation"), with a publicity period of 7 days.
SHR-A1921 for injection is an antibody-drug conjugate (ADC) that targets TROP-2 tumor-associated antigen. By binding to the target antigen on the surface of tumor cells, the drug is endocytosed into the cells and then releases small molecule toxins to kill tumor cells. TROP-2 is a widely expressed glycoprotein antigen that can promote the proliferation, invasion, metastasis and spread of tumor cells. Its high expression is closely related to shortened survival and poor prognosis of tumor patients.
